Open Payments

Childrens Mercy Hospital

Type
Teaching hospital
Where
KANSAS CITY, MO
Medicare CCN
263302
Received
$4,101,213 in 634 records, 2025 ($225,191 general, $3,876,021 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment27$225,191
2025Research payment607$3,876,021

By company

CompanyRecordsAmountYears
Ultragenyx Pharmaceutical Inc.77$802,0482025
SANOFI PASTEUR INC.21$649,6002025
JAZZ PHARMACEUTICALS INC.4$417,4192025
VERTEX PHARMACEUTICALS INCORPORATED5$330,7382025
Rhythm Pharmaceuticals, Inc.213$235,4472025
Edwards Lifesciences Corporation50$184,1412025
Gen-Probe, Inc.5$176,4572025
Alexion Pharmaceuticals, Inc.4$161,2282025
Merck Sharp & Dohme LLC7$112,7342025
ALBIREO PHARMA, INC.43$106,0792025
OrthoPediatrics Corp.3$90,0002025
ACADIA Pharmaceuticals Inc26$88,5852025
Janssen Research & Development, LLC1$82,5002025
GE HEALTHCARE3$61,1942025
Novo Nordisk AS27$60,9192025
Dexcom, Inc.6$56,9172025
Travere Therapeutics, Inc.21$47,0522025
Luminex Corporation1$46,3372025
Ionis Pharmaceuticals, Inc.5$38,2062025
Immedica Pharma US, Inc.8$36,1132025
Gilead Sciences, Inc.14$31,7072025
Bayer Healthcare Pharmaceuticals Inc.12$29,3892025
GENZYME CORPORATION2$26,5972025
QIAGEN, LLC1$23,3612025
Amgen Inc.5$20,6242025
ABBVIE INC.10$20,0272025
PFIZER INC.6$16,8212025
Medtronic, Inc.2$16,4602025
UCB Biosciences Inc.1$15,5952025
Genentech, Inc.4$10,5762025
National Marrow Donor Program4$10,4952025
Novo Nordisk Health Care AG4$9,9602025
New York Blood Center, Inc.1$9,2002025
Ardelyx, Inc.3$9,1872025
Stryker Corporation1$8,6522025
Syndax Pharmaceuticals, Inc.2$7,9502025
Vifor Pharma, Inc.1$5,6002025
Vifor (International) Ltd.1$5,6002025
SANOFI US SERVICES INC.1$5,5002025
bioMerieux Inc1$5,0002025
AKEBIA THERAPEUTICS INC1$4,3302025
Olympus Corporation of the Americas1$4,0002025
AstraZeneca UK Limited1$3,9552025
BioFire Diagnostics, LLC1$3,7092025
Hyperfine Operations, Inc.1$3,2502025
Hoffmann-La Roche Limited3$2,1002025
Chiesi USA, Inc.2$1,4002025
Linvatec Corporation1$1,2732025
Incyte Corporation1$1,0002025
ZOLL Medical Corporation1$7502025

By nature of payment

NatureRecordsAmount
Research payment607$3,876,021
Compensation for services other than consulting, including serving as faculty or as a speaker at a v6$102,195
Consulting Fee3$90,000
Long term medical supply or device loan8$23,521
Space rental or facility fees (teaching hospital only)6$4,550
Grant1$4,000
Education1$700
Charitable Contribution2$225

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-31Stryker Corporation$8,652Long term medical supply or device loanIn-kind items and servicesNA Device, INSTRUMENTS2025
2025-12-31Merck Sharp & Dohme LLC$1,941Research paymentIn-kind items and services Biological, ONCOLOGYLIGHTBEAM-U01 Substudy 01C# A Phase 1,2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatr2025
2025-12-31Merck Sharp & Dohme LLC$1,168Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYLIGHTBEAM-U01 Substudy 01A# A Phase 1,2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatri2025
2025-12-31Merck Sharp & Dohme LLC$449Research paymentIn-kind items and servicesJANUVIA Drug, ENDOCRINOLOGYA Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficac2025
2025-12-31Merck Sharp & Dohme LLC$393Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYLIGHTBEAM-U01 Substudy 01B# A Phase 1,2 Substudy to Evaluate the Safety and Efficacy of Pembrolizumab in Combination Wit2025
2025-12-31Masimo Corporation$142Long term medical supply or device loanIn-kind items and servicesSET and rainbow SET Device, Devices2025
2025-12-31Masimo Corporation$142Long term medical supply or device loanIn-kind items and servicesSET and rainbow SET Device, Devices2025
2025-12-31Masimo Corporation$142Long term medical supply or device loanIn-kind items and servicesSET and rainbow SET Device, Devices2025
2025-12-31Masimo Corporation$142Long term medical supply or device loanIn-kind items and servicesSET and rainbow SET Device, Devices2025
2025-12-31Fisher & Paykel Healthcare Inc$65Long term medical supply or device loanIn-kind items and servicesFISHER & PAYKEL HEALTHCARE Device, Heated respiratory humidifier2025
2025-12-24Edwards Lifesciences Corporation$4,590Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012025
2025-12-24Edwards Lifesciences Corporation$3,200Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2025
2025-12-24Edwards Lifesciences Corporation$854Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012025
2025-12-24Edwards Lifesciences Corporation$531Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2025
2025-12-22Bayer Healthcare Pharmaceuticals Inc.$4,120Research paymentCash or cash equivalentKerendia Drug, Cardio-RenalA 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of2025
2025-12-22Novo Nordisk AS$1,000Research paymentCash or cash equivalentSogroya Biological, Growth HormoneNN8640-44672025
2025-12-22Novo Nordisk AS$150Research paymentCash or cash equivalentSogroya Biological, Growth HormoneNN8640-44672025
2025-12-18ALBIREO PHARMA, INC.$1,000Research paymentCash or cash equivalentBylvay Drug, GastroenterologyA Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Childr2025
2025-12-16SANOFI PASTEUR INC.$44,000Research paymentCash or cash equivalentStudy of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle2025
2025-12-16Gilead Sciences, Inc.$2,339Research paymentCash or cash equivalentVemlidy Drug, HBVA Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala2025
2025-12-16Gilead Sciences, Inc.$264Research paymentCash or cash equivalentVemlidy Drug, HBVA Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala2025
2025-12-15Rhythm Pharmaceuticals, Inc.$5,737Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-15Rhythm Pharmaceuticals, Inc.$4,590Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-15Genentech, Inc.$2,276Research paymentCash or cash equivalentActemra Biological, ImmunologyA PHASE 1 2 TRIAL OF GLOFITAMAB WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH R R B NHL2025
2025-12-15Rhythm Pharmaceuticals, Inc.$2,000Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-15Rhythm Pharmaceuticals, Inc.$1,500Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-15Rhythm Pharmaceuticals, Inc.$967Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-15Rhythm Pharmaceuticals, Inc.$733Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-15Rhythm Pharmaceuticals, Inc.$410Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-15Rhythm Pharmaceuticals, Inc.$307Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-15Rhythm Pharmaceuticals, Inc.$116Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-15Rhythm Pharmaceuticals, Inc.$100Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-15Rhythm Pharmaceuticals, Inc.$93Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-15Rhythm Pharmaceuticals, Inc.$90Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-15Rhythm Pharmaceuticals, Inc.$83Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-15Rhythm Pharmaceuticals, Inc.$58Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-15Rhythm Pharmaceuticals, Inc.$41Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-12Medtronic, Inc.$12,960Long term medical supply or device loanIn-kind items and servicesINVOS Device, Cerebral/Somatic Oximetry2025
2025-12-12Rhythm Pharmaceuticals, Inc.$3,352Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-12Rhythm Pharmaceuticals, Inc.$3,352Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-12Rhythm Pharmaceuticals, Inc.$3,352Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-12Rhythm Pharmaceuticals, Inc.$2,734Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-12Rhythm Pharmaceuticals, Inc.$2,734Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-12Rhythm Pharmaceuticals, Inc.$2,720Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-12Rhythm Pharmaceuticals, Inc.$2,720Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-09Travere Therapeutics, Inc.$4,335Research paymentCash or cash equivalentA Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Tre2025
2025-12-08Ultragenyx Pharmaceutical Inc.$71,922Research paymentCash or cash equivalentGTX-102-CL3012025
2025-12-05Rhythm Pharmaceuticals, Inc.$3,442Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-05Rhythm Pharmaceuticals, Inc.$2,295Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-05Rhythm Pharmaceuticals, Inc.$1,500Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-05Rhythm Pharmaceuticals, Inc.$998Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-05Rhythm Pharmaceuticals, Inc.$506Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-05Rhythm Pharmaceuticals, Inc.$500Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-05Rhythm Pharmaceuticals, Inc.$420Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-05Rhythm Pharmaceuticals, Inc.$256Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-05Rhythm Pharmaceuticals, Inc.$205Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-05Rhythm Pharmaceuticals, Inc.$205Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-05Rhythm Pharmaceuticals, Inc.$125Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-05Rhythm Pharmaceuticals, Inc.$58Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-05Rhythm Pharmaceuticals, Inc.$41Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-01Ultragenyx Pharmaceutical Inc.$2,141Research paymentCash or cash equivalentGTX-102-CL3012025
2025-12-01Travere Therapeutics, Inc.$1,362Research paymentCash or cash equivalentA Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Tre2025
2025-12-01Rhythm Pharmaceuticals, Inc.$70Research paymentIn-kind items and servicesEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-01Rhythm Pharmaceuticals, Inc.$60Research paymentIn-kind items and servicesEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-01Rhythm Pharmaceuticals, Inc.$55Research paymentIn-kind items and servicesEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-01Rhythm Pharmaceuticals, Inc.$55Research paymentIn-kind items and servicesEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-01Rhythm Pharmaceuticals, Inc.$32Research paymentIn-kind items and servicesEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-01Rhythm Pharmaceuticals, Inc.$24Research paymentIn-kind items and servicesEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-12-01Rhythm Pharmaceuticals, Inc.$3Research paymentIn-kind items and servicesEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-11-25Ultragenyx Pharmaceutical Inc.$1,696Research paymentCash or cash equivalentUX143-CL3012025
2025-11-25Ultragenyx Pharmaceutical Inc.$1,350Research paymentCash or cash equivalentUX143-CL3012025
2025-11-25Ultragenyx Pharmaceutical Inc.$1,350Research paymentCash or cash equivalentUX143-CL3012025
2025-11-25Ultragenyx Pharmaceutical Inc.$1,174Research paymentCash or cash equivalentUX143-CL3012025
2025-11-25Ultragenyx Pharmaceutical Inc.$1,128Research paymentCash or cash equivalentUX143-CL3012025
2025-11-25Ultragenyx Pharmaceutical Inc.$364Research paymentCash or cash equivalentUX143-CL3012025
2025-11-20Rhythm Pharmaceuticals, Inc.$3,442Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-11-20Rhythm Pharmaceuticals, Inc.$1,012Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-11-20Rhythm Pharmaceuticals, Inc.$307Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-11-20Rhythm Pharmaceuticals, Inc.$280Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-11-20Rhythm Pharmaceuticals, Inc.$90Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-11-20Rhythm Pharmaceuticals, Inc.$41Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-11-19Edwards Lifesciences Corporation$4,590Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012025
2025-11-19Edwards Lifesciences Corporation$3,600Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2025
2025-11-19Edwards Lifesciences Corporation$569Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012025
2025-11-19Edwards Lifesciences Corporation$354Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2025
2025-11-18ACADIA Pharmaceuticals Inc$389Research paymentCash or cash equivalentACP-101 Drug, HYPERPHAGIA IN PRADER-WILLI SYNDROMEACP-101-3032025
2025-11-18ACADIA Pharmaceuticals Inc$90Research paymentCash or cash equivalentACP-101 Drug, HYPERPHAGIA IN PRADER-WILLI SYNDROMEACP-101-3022025
2025-11-14Azurity Pharmaceuticals, Inc.$40Research paymentCash or cash equivalentFERAHEME Drug, HEMATOLOGYA PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY (COMPARED TO IRON SUCROSE), EFFICACY AND PHA2025
2025-11-12Gen-Probe, Inc.$97,488Research paymentCash or cash equivalentPANTHER FUSION Device, DiagnosticsComparison of nasal swab and nasopharyngeal swab for respiratory testing using Hologic Panther Fusion assay2025
2025-11-06ALBIREO PHARMA, INC.$800Research paymentCash or cash equivalentBylvay Drug, GastroenterologyAn Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary A2025
2025-11-06ALBIREO PHARMA, INC.$550Research paymentCash or cash equivalentBylvay Drug, GastroenterologyA Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Childr2025
2025-11-05Rhythm Pharmaceuticals, Inc.$270Research paymentIn-kind items and servicesEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-11-05Rhythm Pharmaceuticals, Inc.$70Research paymentIn-kind items and servicesEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-11-05Rhythm Pharmaceuticals, Inc.$32Research paymentIn-kind items and servicesEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-11-04Ultragenyx Pharmaceutical Inc.$180,398Research paymentCash or cash equivalentGTX-102-CL3012025
2025-11-04Bayer Healthcare Pharmaceuticals Inc.$690Research paymentCash or cash equivalentKerendia Drug, Cardio-RenalA 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of2025
2025-11-03Ultragenyx Pharmaceutical Inc.$2,914Research paymentCash or cash equivalentUX143-CL3012025
2025-10-30ALBIREO PHARMA, INC.$1,253Research paymentCash or cash equivalentBylvay Drug, GastroenterologyAn Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndro2025
2025-10-30ALBIREO PHARMA, INC.$1,050Research paymentCash or cash equivalentBylvay Drug, GastroenterologyA Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Childr2025
2025-10-29Novo Nordisk AS$2,388Research paymentCash or cash equivalentSogroya Biological, Growth HormoneNN8640-42632025
2025-10-29Novo Nordisk AS$1,797Research paymentCash or cash equivalentSogroya Biological, Growth HormoneNN8640-44672025
2025-10-29Novo Nordisk AS$1,763Research paymentCash or cash equivalentAlhemo Drug, HemophiliaNN7415-48072025
2025-10-28ABBVIE INC.$3,250Research paymentCash or cash equivalentVENCLEXTA Drug, ONCOLOGYB19-061 Ph 3 Pediatric Study of venetoclax and chemotherapy2025
2025-10-28Gilead Sciences, Inc.$3,041Research paymentCash or cash equivalentVemlidy Drug, HBVA Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala2025
2025-10-28ABBVIE INC.$500Research paymentCash or cash equivalentVENCLEXTA Drug, ONCOLOGYB19-061 Ph 3 Pediatric Study of venetoclax and chemotherapy2025
2025-10-28ABBVIE INC.$350Research paymentCash or cash equivalentVENCLEXTA Drug, ONCOLOGYB19-061 Ph 3 Pediatric Study of venetoclax and chemotherapy2025
2025-10-27Ionis Pharmaceuticals, Inc.$26,798Research paymentCash or cash equivalentION582P32025
2025-10-27Ionis Pharmaceuticals, Inc.$4,725Research paymentCash or cash equivalentION582P32025
2025-10-27Ionis Pharmaceuticals, Inc.$3,645Research paymentCash or cash equivalentION582P32025
2025-10-27Ionis Pharmaceuticals, Inc.$2,363Research paymentCash or cash equivalentION582P32025
2025-10-27Ionis Pharmaceuticals, Inc.$675Research paymentCash or cash equivalentION582P32025
2025-10-25Edwards Lifesciences Corporation$5,100Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012025
2025-10-25Edwards Lifesciences Corporation$2,000Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2025
2025-10-25Edwards Lifesciences Corporation$284Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012025
2025-10-25Edwards Lifesciences Corporation$177Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2025
2025-10-23Bayer Healthcare Pharmaceuticals Inc.$520Research paymentCash or cash equivalentKerendia Drug, Cardio-RenalA 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of2025
2025-10-23Azurity Pharmaceuticals, Inc.$300Research paymentCash or cash equivalentFERAHEME Drug, HEMATOLOGYA PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY (COMPARED TO IRON SUCROSE), EFFICACY AND PHA2025
2025-10-22SANOFI US SERVICES INC.$5,500Research paymentCash or cash equivalentTZIELD Biological, Endocrine & Metabolic DiseasesA Multicenter, Multinational Extension of Study PRV-031-001 to Evaluate the Long-Term Safety of Teplizumab (PRV-031), a 2025
2025-10-21Gilead Sciences, Inc.$3,041Research paymentCash or cash equivalentVemlidy Drug, HBVA Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala2025
2025-10-17National Marrow Donor Program$4,405Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-10-14SANOFI PASTEUR INC.$69,000Research paymentCash or cash equivalentA Phase 1/2, Parallel-group, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Ranging Study to 2025
2025-10-14Dexcom, Inc.$43,102Research paymentCash or cash equivalentDEXCOM G7 GSS (161) Medical Supply, EndocrinologyPOST APPROVAL STUDY FOR NON-ADJUNCTIVE USE OF DEXCOM G5 AND G6 CGM SYSTEM FOR DIABETES MANAGEMENT (COACH)2025
2025-10-14ALBIREO PHARMA, INC.$15,520Research paymentCash or cash equivalentBylvay Drug, GastroenterologyAn Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndro2025
2025-10-14ACADIA Pharmaceuticals Inc$14,114Research paymentCash or cash equivalentACP-101 Drug, HYPERPHAGIA IN PRADER-WILLI SYNDROMEACP-101-3032025
2025-10-14ACADIA Pharmaceuticals Inc$3,404Research paymentCash or cash equivalentACP-101 Drug, HYPERPHAGIA IN PRADER-WILLI SYNDROMEACP-101-3022025
2025-10-14Dexcom, Inc.$2,280Research paymentCash or cash equivalentDEXCOM G7 GSS (161) Medical Supply, EndocrinologyPOST APPROVAL STUDY FOR NON-ADJUNCTIVE USE OF DEXCOM G5 AND G6 CGM SYSTEM FOR DIABETES MANAGEMENT (COACH)2025
2025-10-14ALBIREO PHARMA, INC.$585Research paymentCash or cash equivalentBylvay Drug, GastroenterologyAn Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndro2025
2025-10-09ALBIREO PHARMA, INC.$1,237Research paymentCash or cash equivalentBylvay Drug, GastroenterologyAn Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndro2025
2025-10-08Rhythm Pharmaceuticals, Inc.$1,500Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-08Rhythm Pharmaceuticals, Inc.$1,012Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-08Rhythm Pharmaceuticals, Inc.$205Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-08Rhythm Pharmaceuticals, Inc.$90Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-08Rhythm Pharmaceuticals, Inc.$70Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-08Rhythm Pharmaceuticals, Inc.$70Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-08Rhythm Pharmaceuticals, Inc.$68Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-08Rhythm Pharmaceuticals, Inc.$41Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-08Rhythm Pharmaceuticals, Inc.$31Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-03Ultragenyx Pharmaceutical Inc.$4,050Research paymentCash or cash equivalentUX143-CL3012025
2025-10-03Ultragenyx Pharmaceutical Inc.$1,012Research paymentCash or cash equivalentUX143-CL3012025
2025-10-03Ultragenyx Pharmaceutical Inc.$909Research paymentCash or cash equivalentUX143-CL3012025
2025-10-03Ultragenyx Pharmaceutical Inc.$36Research paymentCash or cash equivalentUX143-CL3012025
2025-10-02Rhythm Pharmaceuticals, Inc.$3,352Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-02Rhythm Pharmaceuticals, Inc.$3,352Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-02Rhythm Pharmaceuticals, Inc.$3,114Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-02Rhythm Pharmaceuticals, Inc.$3,114Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-02Rhythm Pharmaceuticals, Inc.$3,114Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-02Rhythm Pharmaceuticals, Inc.$3,114Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-02Rhythm Pharmaceuticals, Inc.$3,114Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-02Rhythm Pharmaceuticals, Inc.$2,720Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-02Rhythm Pharmaceuticals, Inc.$2,720Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-02Rhythm Pharmaceuticals, Inc.$2,720Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-02Rhythm Pharmaceuticals, Inc.$2,720Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-02Rhythm Pharmaceuticals, Inc.$2,720Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-02Rhythm Pharmaceuticals, Inc.$2,720Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-02Rhythm Pharmaceuticals, Inc.$2,720Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-02Rhythm Pharmaceuticals, Inc.$2,720Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-02Rhythm Pharmaceuticals, Inc.$2,720Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-02Rhythm Pharmaceuticals, Inc.$2,720Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-02Rhythm Pharmaceuticals, Inc.$2,720Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-02Rhythm Pharmaceuticals, Inc.$2,720Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-02Rhythm Pharmaceuticals, Inc.$2,720Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-02ABBVIE INC.$2,327Research paymentCash or cash equivalentVENCLEXTA Drug, ONCOLOGYB19-061 Ph 3 Pediatric Study of venetoclax and chemotherapy2025
2025-10-02Rhythm Pharmaceuticals, Inc.$972Research paymentCash or cash equivalentEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-01Rhythm Pharmaceuticals, Inc.$270Research paymentIn-kind items and servicesEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-01Rhythm Pharmaceuticals, Inc.$270Research paymentIn-kind items and servicesEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-01Rhythm Pharmaceuticals, Inc.$270Research paymentIn-kind items and servicesEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-01Rhythm Pharmaceuticals, Inc.$270Research paymentIn-kind items and servicesEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-01Rhythm Pharmaceuticals, Inc.$270Research paymentIn-kind items and servicesEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-01Rhythm Pharmaceuticals, Inc.$270Research paymentIn-kind items and servicesEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-01Rhythm Pharmaceuticals, Inc.$110Research paymentIn-kind items and servicesEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-01Rhythm Pharmaceuticals, Inc.$55Research paymentIn-kind items and servicesEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-01Rhythm Pharmaceuticals, Inc.$55Research paymentIn-kind items and servicesEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-01Rhythm Pharmaceuticals, Inc.$30Research paymentIn-kind items and servicesEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-01Rhythm Pharmaceuticals, Inc.$24Research paymentIn-kind items and servicesEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-01Rhythm Pharmaceuticals, Inc.$24Research paymentIn-kind items and servicesEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-01Rhythm Pharmaceuticals, Inc.$15Research paymentIn-kind items and servicesEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-01Rhythm Pharmaceuticals, Inc.$15Research paymentIn-kind items and servicesEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-10-01Rhythm Pharmaceuticals, Inc.$15Research paymentIn-kind items and servicesEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-09-29SANOFI PASTEUR INC.$11,500Research paymentCash or cash equivalentA Phase IIb, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of an RSV Vaccine2025
2025-09-25Edwards Lifesciences Corporation$9,690Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012025
2025-09-25Edwards Lifesciences Corporation$4,000Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2025
2025-09-25ALBIREO PHARMA, INC.$2,436Research paymentCash or cash equivalentBylvay Drug, GastroenterologyAn Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary A2025
2025-09-25ALBIREO PHARMA, INC.$600Research paymentCash or cash equivalentBylvay Drug, GastroenterologyA Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Childr2025
2025-09-25Bayer Healthcare Pharmaceuticals Inc.$520Research paymentCash or cash equivalentKerendia Drug, Cardio-RenalA 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of2025
2025-09-25Edwards Lifesciences Corporation$300Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012025
2025-09-25Edwards Lifesciences Corporation$284Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 2015-012025
2025-09-25Edwards Lifesciences Corporation$177Research paymentCash or cash equivalentEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart ValvesCOMPASSION S3 Post Approval Study (2020-07)2025
2025-09-24UCB Biosciences Inc.$15,595Research paymentCash or cash equivalentFintepla Drug, NeurologyEvaluating the safety of fenfluramine (Fintepla) for Dravet syndrome, Lennox-Gastaut syndrome, and other epilepsy patien2025
2025-09-24ACADIA Pharmaceuticals Inc$5,941Research paymentCash or cash equivalentACP-101 Drug, HYPERPHAGIA IN PRADER-WILLI SYNDROMEACP-101-3022025
2025-09-24ACADIA Pharmaceuticals Inc$5,400Research paymentCash or cash equivalentACP-101 Drug, HYPERPHAGIA IN PRADER-WILLI SYNDROMEACP-101-3022025
2025-09-24ACADIA Pharmaceuticals Inc$914Research paymentCash or cash equivalentACP-101 Drug, HYPERPHAGIA IN PRADER-WILLI SYNDROMEACP-101-3022025
2025-09-24ACADIA Pharmaceuticals Inc$682Research paymentCash or cash equivalentACP-101 Drug, HYPERPHAGIA IN PRADER-WILLI SYNDROMEACP-101-3022025
2025-09-24ACADIA Pharmaceuticals Inc$299Research paymentCash or cash equivalentACP-101 Drug, HYPERPHAGIA IN PRADER-WILLI SYNDROMEACP-101-3022025
2025-09-24ACADIA Pharmaceuticals Inc$90Research paymentCash or cash equivalentACP-101 Drug, HYPERPHAGIA IN PRADER-WILLI SYNDROMEACP-101-3022025
2025-09-24ACADIA Pharmaceuticals Inc$82Research paymentCash or cash equivalentACP-101 Drug, HYPERPHAGIA IN PRADER-WILLI SYNDROMEACP-101-3022025
2025-09-23Ultragenyx Pharmaceutical Inc.$2,569Research paymentCash or cash equivalentUX143-CL3012025
2025-09-22SANOFI PASTEUR INC.$66,700Research paymentCash or cash equivalentA Phase 1, Parallel, Randomized, Multi-center Study to Evaluate the Safety and Immunogenicity of Different Formulations 2025
2025-09-22Travere Therapeutics, Inc.$40Research paymentCash or cash equivalentA Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Tre2025
2025-09-20Rhythm Pharmaceuticals, Inc.$240Research paymentIn-kind items and servicesEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025
2025-09-20Rhythm Pharmaceuticals, Inc.$49Research paymentIn-kind items and servicesEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway2025

The latest 200 records of 634.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Jackson CountyKansas City city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Kansas City, MO, county Jackson County, MO, state Missouri; placed by its city name.

MeasurePlace (city or town)
Kansas City, MO
County
Jackson County, MO
State
Missouri
Population B01003510,612719,9766,191,814
Population, 2020 census P1508,090717,2046,154,913
Median age B0100235.837.039.0
Under 18 B0100122.5%23.3%22.3%
65 and over B0100114.3%15.9%17.9%
Households B11001221,979306,7982,508,227
Foreign born B050028.6%6.6%4.5%
Median household income B19013$69,166$68,577$70,702
Median family income B19113$92,934$90,585$91,360
Per capita income B19301$41,393$39,559$39,695
Poverty rate B1700114.6%14.1%12.6%
Unemployment rate B230254.4%4.7%4.0%
Civilian labor force B23025279,828381,4333,120,639
Mean commute (minutes) B0801321.723.423.5
Bachelor's degree or higher B1500338.4%34.0%32.4%
Housing units B25001245,346336,2882,825,287
Owner-occupied B2500355.4%59.1%68.1%
Renters B2500344.6%40.9%31.9%
Median home value B25077$242,900$230,500$230,300
Median gross rent B25064$1,238$1,197$1,033
White, not Hispanic B0300254.0%59.3%76.3%
Black B0300225.2%22.0%10.9%
Hispanic or Latino B0300212.5%11.4%5.2%
Asian B030022.8%1.8%2.1%
American Indian and Alaska Native B030020.1%0.1%0.2%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Kansas City, MO.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.